| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Syrosingopine |
Is a |
True |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Reserpine - chemical |
Is a |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Rescinnamine |
Is a |
True |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Alpha-2 adrenergic receptor agonist |
Is a |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing alpha-2 adrenergic receptor agonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing deserpidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| dexmedetomidinhydrochlorid 100 µg/ml injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Deserpidine 250 microgram and methyclothiazide 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely deserpidine 500 microgram and methyclothiazide 5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| centralt virkende blodtrykssænkende middel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| reserpin 100 % |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Chlorothiazide 250 mg and reserpine 125 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely chlorothiazide 500 milligram and reserpine 125 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg and reserpine 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 25 mg and reserpine 125 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 50 mg and reserpine 125 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyclothiazide 2.5 mg and reserpine 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorothiazide and reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydrochlorothiazide and reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing deserpidine and methyclothiazide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| hydralazinhydrochlorid + hydrochlorthiazid + reserpin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing methyclothiazide and reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| guanfacinhydrochlorid 1 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Chlorothiazide 250 mg and methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine-containing product in transdermal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 1mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| apraclonidin 1% intraokulær opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 100microgram extended release film |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidinhydrochlorid 100 µg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing clonidine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Lofexidine hydrochloride 200 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| chlortalidon + clonidinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing dexmedetomidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 100 microgram/mL prolonged-release oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 4mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidin 7,5 mg/enhed |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidin 2,5 mg/enhed |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing guanabenz (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 25 mg and methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 200microgram extended release film |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidinhydrochlorid 150 µg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| guanfacinhydrochlorid 2 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Apraclonidine (as apraclonidine hydrochloride) 5 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 50 mg and methyldopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing apraclonidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 250 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing guanfacine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 30 mg and methyldopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 3mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 15 mg and methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidin 5 mg plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidin 0,1 mg plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Chlortalidone 15 mg and clonidine hydrochloride 200 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidinhydrochlorid 0,5 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanabenz acetate 8 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 2mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing clonidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clonidine hydrochloride 300 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely chlortalidone 15 milligram and clonidine hydrochloride 300 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanabenz acetate 4 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| guanfacinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydrochlorothiazide and methyldopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing methyldopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 300microgram extended release film |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing lofexidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidin 4 mg plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorothiazide and methyldopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| clonidinhydrochlorid kapsel med modificeret udløsning a 250 µg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 200 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clonidine hydrochloride 25 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing methyldopa in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| central alfa-receptor-agonist |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
FHIR